Yazılar

Nvidia Completes $700 Million Acquisition of Run:ai After Regulatory Scrutiny

/in /tarafından

Nvidia has successfully completed its $700 million acquisition of Israeli AI startup Run:ai, following regulatory scrutiny from antitrust authorities. The European Commission granted unconditional approval for the deal earlier in December, after initially flagging concerns about potential competition issues. The acquisition, which had been under investigation due to Nvidia’s dominant position in the graphics processing unit (GPU) market, was cleared after the Commission determined it would not hinder competition. The U.S. Department of Justice is also reviewing the deal on antitrust grounds. Run:ai, known for its AI infrastructure optimization tools, announced plans to make its software open-source, extending its compatibility beyond Nvidia’s GPUs to support the broader AI ecosystem.

 

Regulatory Conditions Cleared for Novo Holdings’ $16.5 Billion Catalent Acquisition

/in /tarafından

Novo Holdings announced on Saturday that all regulatory conditions for its $16.5 billion acquisition of U.S. contract drug manufacturer Catalent have been fulfilled. The companies anticipate completing the transaction in the coming days.

The acquisition, initially agreed upon in February, is part of Novo Holdings’ strategy to increase production of the blockbuster weight-loss drug Wegovy, developed by its affiliate Novo Nordisk. As part of the agreement, Novo Holdings will sell three of Catalent’s factories located in Italy, Belgium, and the United States to Novo Nordisk for $11 billion. These facilities specialize in filling injection pens under sterile conditions.

Novo Holdings is the controlling shareholder of Novo Nordisk, the Danish pharmaceutical giant behind the popular GLP-1 injectable drug Wegovy. Novo Nordisk stated that while the acquisition aligns with its strategic goals, it is expected to have a mid single-digit negative impact on operating profit growth in 2025. Consequently, the company does not plan to initiate a share buyback program for the year.

Regulatory and Antitrust Scrutiny

The deal has faced close regulatory scrutiny. Earlier in December, the European Commission granted EU antitrust approval, stating that the merger posed no competition concerns within the European Economic Area (EEA).

In the United States, the acquisition drew criticism from consumer groups, labor unions, and policymakers. U.S. Senator Elizabeth Warren urged the Federal Trade Commission (FTC) to scrutinize the deal, citing potential concerns. The FTC had requested additional information on the acquisition in May, but no further updates have been issued.

Strategic Implications

The transaction underscores Novo Holdings’ commitment to expanding its role in the manufacturing and distribution of high-demand pharmaceuticals. By integrating Catalent’s production capabilities, Novo Holdings aims to meet the growing demand for weight-loss treatments while maintaining compliance with global competition regulations.

 

China Launches Antitrust Probe Into Nvidia Amid US-China Chip Tensions

/in /tarafından

China announced on Monday it has launched an antitrust investigation into Nvidia, targeting alleged violations of the country’s anti-monopoly law. This move is seen as a countermeasure to recent U.S. restrictions on China’s semiconductor industry, escalating tensions in the ongoing tech rivalry between the two nations.

The State Administration for Market Regulation (SAMR) stated that Nvidia, known for its AI and gaming chips, is under scrutiny for potentially breaching conditions set during its 2020 acquisition of Israeli chipmaker Mellanox Technologies. While details remain scarce, the regulator mentioned suspicions about Nvidia violating commitments to supply products on “fair, reasonable, and non-discriminatory” terms, among other stipulations.

Retaliatory Backdrop

This probe follows heightened tensions between Washington and Beijing. Last week, the U.S. introduced new restrictions on 140 Chinese companies, further curbing China’s access to advanced semiconductor technology. In response, Beijing banned exports of critical minerals like gallium, germanium, and antimony to the U.S.

In addition, four major Chinese industry associations called on domestic firms to reduce reliance on U.S. chips, labeling them “unsafe” and encouraging purchases from local suppliers. Nvidia, which once commanded over 90% of China’s AI chip market, has faced diminishing revenue from China, dropping from 26% of its global total two years ago to 17% by January 2023.

Nvidia’s shares fell by 2.5% on Monday following the announcement. The company stated it would cooperate with regulators and reaffirmed its commitment to honoring agreements in all regions. However, analysts like Bob O’Donnell from TECHnalysis Research believe the investigation’s immediate impact on Nvidia will be limited, as U.S. restrictions already prevent the sale of its most advanced chips to China.

Nvidia’s Strategic Adjustments

U.S. sanctions in 2022 prohibited Nvidia from selling its A100 and H100 AI chips to China, prompting the company to create modified versions for the Chinese market. Further tightened U.S. export controls in 2023 led Nvidia to develop new variants tailored to Chinese restrictions. Despite these challenges, Nvidia faces mounting competition from domestic players like Huawei.

China’s Antitrust Track Record

China’s antitrust probes into foreign tech companies are not new. The most prominent case occurred in 2013, when China fined Qualcomm $975 million for market abuse in wireless communication standards. Similar to that case, Nvidia is accused of practices such as discriminatory terms, product bundling, and unfair supply conditions—issues tied to the Mellanox acquisition conditions.

The investigation could signal Beijing’s intent to leverage regulatory tools to counter U.S. sanctions while fostering its domestic chip industry.